Literature DB >> 10958942

Characterization of the topoisomerase I locus in human colorectal cancer.

A Boonsong1, S Marsh, P H Rooney, D A Stevenson, J Cassidy, H L McLeod.   

Abstract

DNA topoisomerase I (topo I) is the principle target for Camptothecin and its analogues. The topo I gene is located on chromosome 20q11.2-q13.1 and variation in topo I gene copy number has been shown to have impact on the in vitro sensitivity to topoisomerase I inhibitor chemotherapy. Fluorescence in situ hybridization (FISH) was used to detect and compare the TOPO I gene copy number between metaphase and interphase nuclei in a panel of 7 colorectal cancer cell lines. TOPO I gene copy number varied from 2 to 8 between cell lines, and signal in interphase nuclei demonstrated a linear relationship with that detected in metaphase nuclei. The structure of gene amplification included isochromosome formation, amplicon extension, and marker chromosome generation. Comparative genomic hybridization (CGH) was then used to further define the region of gain on chromosome 20. The region of gain contained the topo I gene and involved nearly all of 20q in most cases. This demonstrates a high degree of intrinsic variation in topo I gene copy number and the involvement of a 20q amplicon in colorectal cancer, which may have important implications for colorectal tumorigenesis and the use of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958942     DOI: 10.1016/s0165-4608(00)00242-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

1.  PDRG1, a novel tumor marker for multiple malignancies that is selectively regulated by genotoxic stress.

Authors:  Lingyan Jiang; Xiuquan Luo; Jingxue Shi; Hong Sun; Qing Sun; M Saeed Sheikh; Ying Huang
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

2.  Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.

Authors:  Ida Marie Heeholm Sønderstrup; Sune Boris Nygård; Tim Svenstrup Poulsen; Dorte Linnemann; Jan Stenvang; Hans Jørgen Nielsen; Jiri Bartek; Nils Brünner; Peter Nørgaard; Lene Riis
Journal:  Mol Oncol       Date:  2015-03-04       Impact factor: 6.603

Review 3.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

4.  Topoisomerase levels determine chemotherapy response in vitro and in vivo.

Authors:  Darren J Burgess; Jason Doles; Lars Zender; Wen Xue; Beicong Ma; W Richard McCombie; Gregory J Hannon; Scott W Lowe; Michael T Hemann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

5.  Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.

Authors:  David Hersi Smith; Ib Jarle Christensen; Niels Frank Jensen; Bo Markussen; Maria Unni Rømer; Sune Boris Nygård; Sven Müller; Hans Jørgen Nielsen; Nils Brünner; Kirsten Vang Nielsen
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

6.  Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells.

Authors:  W Wang; J Cassidy
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

7.  Topoisomerase I as a biomarker: detection of activity at the single molecule level.

Authors:  Joanna Proszek; Amit Roy; Ann-Katrine Jakobsen; Rikke Frøhlich; Birgitta R Knudsen; Magnus Stougaard
Journal:  Sensors (Basel)       Date:  2014-01-10       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.